Clinical trial • Phase I • Nephrology
WAL0623 for Glomerular kidney disease with proteinuria|IgA nephropathy|Membranous nephropathy|Glomerulonephritis|Focal segmental glomerulosclerosis|Alport syndrome
Phase I trial of WAL0623 for Glomerular kidney disease with proteinuria|IgA nephropathy|Membranous nephropathy|Glomerulonephritis|Focal segmental glomerul…
Overview
- Trial Therapeutic Area
- Nephrology
- Trial Disease
- Glomerular kidney disease with proteinuria|IgA nephropathy|Membranous nephropathy|Glomerulonephritis|Focal segmental glomerulosclerosis|Alport syndrome
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 06-10-2025
- First CTIS Authorization Date
- 27-01-2026
Trial design
Phase I trial across 1 site in Italy.
- Target Sample Size
- 84
Eligibility
Recruits 84 Vulnerable population not selected; trial population listed as Healthy volunteers; no consent or assent handling for vulnerable populations specified..
- Vulnerable Population
- Vulnerable population not selected; trial population listed as Healthy volunteers; no consent or assent handling for vulnerable populations specified.
Recruitment
- Planned Sample Size
- 84
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 84
Italy
- Earliest CTIS Part Ii Submission Date
- 23-12-2025
- Latest Decision Or Authorization Date
- 27-01-2026
- Processing Time Days
- 35
- Number Of Sites
- 1
- Number Of Participants
- 84
Sites
- Site Name
- Centro Ricerche Cliniche Di Verona S.r.l.
- Contact Person Name
- Luigi Ziviani
- Contact Person Email
- luigi.ziviani@crc.vr.it
Sponsor
Primary sponsor
- Full Name
- Walden Biosciences Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- WAL0623
Related trials
Other published trials that may interest you.